低级别胶质瘤患者血液和肿瘤组织中缺乏针对IDH1R132H的B细胞和T细胞反应
该研究检测了IDH1R132H突变低级别胶质瘤患者血液和肿瘤组织中对突变新表位的B细胞和T细胞反应。采用ELISA检测27例患者血清中特异性抗体,流式细胞术和ELISA检测36例外周血单个核细胞和10例肿瘤浸润淋巴细胞的T细胞活化标志和IFN-γ产生。结果未检测到IDH1R132H特异性IgG或CD4 T细胞反应,表明该表位免疫原性不足。
要点
- IDH1R132H在低级别胶质瘤中高频突变,但患者血清中未检测到特异性IgG。
- 外周血和肿瘤浸润淋巴细胞中均未观察到针对IDH1R132H的CD4 T细胞反应。
- IDH1R132H免疫原性不足,限制了其作为T细胞治疗靶点的进一步开发。
核心结论
- IDH1R132H在低级别胶质瘤患者中缺乏体液和细胞免疫反应,免疫原性不足。
研究设计与样本
- 研究纳入IDH1R132H突变低级别胶质瘤患者,检测血清抗体、外周血单个核细胞和肿瘤浸润淋巴细胞的T细胞反应。
主要发现
- 27例患者血清中未检测到IDH1R132H特异性IgG。
- 36例外周血单个核细胞和10例肿瘤浸润淋巴细胞中未观察到针对IDH1R132H的CD4 T细胞反应。
临床怎么用
- 提示IDH1R132H可能不适用于大多数低级别胶质瘤患者的T细胞治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Mutations in the isocitrate dehydrogenase-1 gene (IDH1) occur at high frequency in grade II-III gliomas (LGGs). IDH1 mutations are somatic, missense and heterozygous affecting codon 132 in the catalytic pocket of the enzyme. In LGG, most mutations (90%) result in an arginine to histidine substitution (IDH1R132H) providing a neo-epitope that is expressed in all tumor cells. To assess the immunogenic nature of this epitope, and its potential use to develop T cell treatments, we measured IDH1R132H-specific B and T cell reactivity in blood and tumor tissue of LGG patients. METHODS: Sera from IDH1R132H-mutated LGG patients (n = 27) were assayed for the presence of a neo-specific antibody response using ELISA. In addition, PBMCs (n = 36) and tumor-infiltrating lymphocytes (TILs, n = 10) were measured for T cell activation markers and IFN-γ production by flow cytometry and ELISA. In some assays, frequencies of CD4 T cells specific for mutated peptide presented by HLA-DR were enriched prior to T cell monitoring assays. RESULTS: Despite high sensitivity of our assay, we failed to detect IDH1R132H-specific IgG in sera of LGG patients. Similarly, we did not observe CD4 T cell reactivity towards IDH1R132H in blood, neither did we observe such reactivity following pre-enrichment of frequencies of IDH1R132H-specific CD4 T cells. Finally, we did not detect IDH1R132H-specific CD4 T cells among TILs. CONCLUSIONS: The absence of both humoral and cellular responses in blood and tumors of LGG patients indicates that IDH1R132H is not sufficiently immunogenic and devaluates its further therapeutic exploitation, at least in the majority of LGG patients.
引用
- Weenink B, van Brakel M, Wijers R, et al. Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients. J Neurooncol. 2019. PMID: 31240524. doi:10.1007/s11060-019-03228-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。